Results 121 to 130 of about 21,018 (198)

EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells

, 2020
Sanja Nabergoj, Tijana Markovič, Damjan Avsec, Martina Gobec, Helena Podgornik, Žiga Jakopin, Irena Mlinarič‐Raščan   +6 more
openalex   +1 more source

Nanomechanical and Thermodynamic Alterations of Red Blood Cells in Chronic Lymphocytic Leukemia: Implications for Disease and Treatment Monitoring. [PDF]

Int J Mol Sci
Strijkova V, Katrova V, Ivanova M, Langari A, Gartcheva L, Guenova M, Alexandrova-Watanabe A, Taneva SG, Krumova S, Todinova S.   +9 more
europepmc   +1 more source

Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. [PDF]

Future Oncol
Dingli D, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt H, Zhang X, Lodaya K, Obeng-Kusi M.   +10 more
europepmc   +1 more source

Supplementary Table S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy [PDF]

Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan O’Brien, Dan Jones, Leo W.K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner   +12 more
openalex   +1 more source

Ibrutinib in Refractory Classic Hodgkin's Lymphoma [PDF]

, 2015
Mehdi Hamadani, Sriram Balasubramanian, Parameswaran Hari   +2 more
openalex   +1 more source

BTK inhibitor ibrutinib reduces LPS-induced inflammation in C8-B4 microglia. [PDF]

EXCLI J
Das D, Mali AS, Greco D, Michalicková D, Novotný J, Slanar O.   +5 more
europepmc   +1 more source

Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program [PDF]

, 2018
Peter Hillmen, Joris Diels, Nollaig Healy, Wafae Iraqi, J Aschan, Mark Wildgust   +5 more
openalex   +1 more source

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China. [PDF]

EClinicalMedicine
Wang T, Yan Y, Wang H, Sun Y, Liu X, Lyu R, Xiong W, An G, Liu W, Xu Y, Deng S, Wang Q, Du C, Huang L, Zou D, Zhao Y, Qiu L, Li Z, Yi S.   +18 more
europepmc   +1 more source

Hope for high risk chronic lymphocytic leukemia after ibrutinib failure

, 2018
Ohad Benjamini
openalex   +1 more source

Life after ibrutinib? A new unmet need in CLL [PDF]

, 2015
Javier Pinilla‐Ibarz, Julio C. Chávez
openalex   +1 more source